Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial (ATEGE-LIVER)
Study of ATEGE-Fresenius Induction in Liver Transplantation Followed by Tacrolimus Weaning.
Sponsor: Astellas Pharma Inc
Terminated
Experimental arm (induction + low dose tacrolimus) not effective.
Other terminated trials from Astellas Pharma Inc
- Primary Mitochondrial Myopathy · Phase PHASE2 · May 2024
- Prostate Cancer · Jan 2024
- Anemia · Phase PHASE3 · Jun 2023
- Metastatic Castration Resistant Prostate Cancer · Phase PHASE1/PHASE2 · Nov 2022
- Breast Cancer · Phase PHASE2 · Sep 2022
More terminations from Astellas Pharma Inc
Other Liver Diseases trials with similar outcome
This PHASE2 trial investigates Liver Diseases and is currently terminated or withdrawn. Astellas Pharma Inc leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
- Fresenius AG
- Hospital Clinic of Barcelona
For direct contact, visit the study record on ClinicalTrials.gov .